An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele

Journal of Investigative Dermatology

Volumn 119, Issue 4, 2002, Pages 961-965

  Bertram, Chandra G ^a   Gaut, Rupert M ^a   Barrett, Jennifer H ^a   Pinney, Elizabeth ^b   Whitaker, Linda ^a   Turner, Faye ^a   Bataille, Veronique ^b   Dos Santos Silva, Isabel ^c   Swerdlow, Anthony J ^d   Bishop, D Timothy ^a   Newton Bishop, Julia A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b Cancer Research   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Ala148Thr; Atypical mole syndrome; CDKN2A; Melanoma; Nevi

Indexed keywords

ALANINE; THREONINE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CDKN2A GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; MISSENSE MUTATION; NEVUS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 18744389747     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.01825.x     Document Type: Article

References (26)

1. Augustsson A, Stierner U, Rosdahl I, Suurkula M: Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 71:518-524, 1990
2. Bataille V, Newton Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K, Cuzick J: Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: A case control study. Br J Cancer 73:1605-1611, 1996
3. Bergman W, Palan A, Went LN: Clinical and genetic studies in six Dutch kindreds with the dysplastic naevus syndrome. Ann Hum Genet 50:249-258, 1986
4. Bergman W, Gruis NA, Frants RR: The Dutch FAMMM family material. Clinical and genetic data. Cytogenet Cell Genet 59:161-164, 1992
5. Easton D, Cox G, Macdonald A, Ponder B: Genetic susceptibility to naevi-A twin study. Br J Cancer 64:1164-1167, 1991
6. Fitzgerald MG, Harkin DP, Silva-Arrieta S, et al: Prevalence of germ-line mutations in p16, p19ARF and CDK4 in familial melanoma: Analysis of a clinic based population. Proc Natl Acad Sci 93:8541-8545, 1996
7. Goldstein AM, Tucker MA: Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 89:676-678, 1997
8. Harland MH, Meloni R, Gruis N, et al: Germline mutations of the CDKN2 gene in UK melanoma families. Hum Molec Genet 6:2061-2067, 1997
9. Harland M, Holland EA, Ghiorzo P, et al: Mutation screening of the CDKN2A promoter in melanoma families. Genes Chrom Cancer 28:45-57, 2000
10. Holland E, Beaton S, Becker T, et al: Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294, 1995
11. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nature Genet 8:15-21, 1994
12. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22-26, 1994
13. Keller-Melchior R, Schmidt R, Piepkorn M: Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 110:932-938, 1998
14. Likischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL: Cancer-associated missense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66:249-254, 1996
15. McCullagh P: Regression models for ordinal data. J R Stat Soc B 42:109-142, 1980
16. Newton JA, Bataille V, Griffiths K, et al: How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 29:989-996, 1993
17. Newton Bishop J, Bataille V, Pinney E, Bishop DT: Family studies in melanoma: Identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res 4:199-206, 1994
18. Newton Bishop JA, Bradburn M, Bergman W, et al: Teaching non-specialist health care professionals how to identify the atypical mole syndrome phenotype: A multi-national study. Br J Dermatol 142:331-337, 2000
19. Ranada K, Hussussian CJ, Sikorski RS, et al: Mutations associated with familial melanoma impair p16 INK4 function. Nature Genet 10:114-116, 1995
20. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
21. Soufir N, Avril MF, Chompret A, et al: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Molec Genet 7:209-216, 1998
22. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JAA, Clark J, Hole D: Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J 292:1555-1560, 1986
23. Uhrbom L, Nister M, Westermark B: Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15:505-514, 1997
24. Wachsmuth RC, Gaut RM, Barrett JH, et al: Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 117:348-352, 2001
25. Walker GJ, Hussussian CJ, Flores JF, et al: Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Molec Genet 4:1845-1852, 1995
26. Zhu G, Duffy DL, Eldridge A, et al: A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: A maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 65:483-492, 1999